OncoMatch/Clinical Trials/NCT07276373
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Is NCT07276373 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Nenocorilant 200 mg and Nenocorilant 300 mg for neoplasms.
Treatment: Nenocorilant 200 mg · Nenocorilant 300 mg · Nenocorilant 400 mg · Nivolumab — This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Cardiac function
QTcF interval >450 msec, family history of long QT syndrome or unexplained sudden death at young age, or requirement for use of medication that may prolong the QTc interval [excluded]
Has adequate organ function; QTcF interval >450 msec, a family history of long QT syndrome or unexplained sudden death at young age, or a requirement for use of medication that may prolong the QTc interval
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 03 · Los Angeles, California
- Site 01 · San Antonio, Texas
- Site 02 · West Valley City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07276373 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify